Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.
View Top Employees from CellCentricWebsite | http://www.cellcentric.com |
Revenue | $7.4 million |
Employees | 40 (40 on RocketReach) |
Founded | 2003 |
Phone | +44 1799 531130 |
Technologies |
JavaScript,
HTML,
Twitter
+6 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare, Science and Engineering, Medical, Health Care, Therapeutics |
Competitors | Egenix INC, Second Genome Inc., U3 Pharma GmbH, Vivoryon Therapeutics N.V., ZEDIRA GmbH |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular CellCentric employee's phone or email?
The CellCentric annual revenue was $7.4 million in 2024.
Debbie Haynes is the COO of CellCentric.
40 people are employed at CellCentric.
The NAICS codes for CellCentric are [325, 32541, 32, 3254].
The SIC codes for CellCentric are [283, 28].